We have found OKT3 to be extremely effective at reversing rejection in primary and resistant rejection episodes of kidney, liver, and pancreas transplant recipients. The rates of recurrent rejection and subsequent graft loss were moderate but represent significant graft salvage. However, the rejection rate was high after its prophylactic use in conjunction with azathioprine and steroids in renal allograft recipients. The viral infection rate was also high, and the development of pancytopenia is particularly worrisome. Reducing or stopping maintenance immunosuppression and restarting it two to three days before the end of OKT3 treatment may reduce infectious complications. A study comparing the efficacy of OKT3 with that of ALG in the treatment of rejection is currently in progress at the University of Minnesota Hospital.
|Original language||English (US)|
|Number of pages||2|
|Issue number||1 SUPPL. 1|
|State||Published - Jan 1 1988|
ASJC Scopus subject areas